Nippon Chemiphar’s Generics Business Continues To Recover
As Japanese Company Sees 2.4% Growth In Generics Segment
Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
You may also be interested in...
In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.
Three strong quarters in a row have prompted Nippon Chemiphar to revise up its FY2021 forecasts, thanks to strong sales of generic drugs launched in FY2020 and June 2021, as well as an increase in demand due to quality control issues faced by competitors.
Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”